Business Context and Reporting Period
This Form 8-K filing by Community Health Systems, Inc. (CYH) reports on events occurring on February 12, 2025, with the report dated February 14, 2025. The filing details the Board of Directors' approval of 2025 compensation arrangements for Named Executive Officers (NEOs), excluding former President and Chief Medical Officer Lynn T. Simon, M.D., who retired on December 31, 2024.
Key Financial Metrics
This filing does not contain operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation structures.
Material Changes and Compensation Details
The Board approved the following compensation components for fiscal year 2025:
Base Salaries
- Tim L. Hingtgen (CEO): $1,365,909
- Kevin J. Hammons (President & CFO): $819,545
- Kevin A. Stockton (EVP Operations): $731,331
- Chad A. Campbell (Regional President): $692,187
Cash Incentive Compensation
Target opportunities are expressed as a percentage of base salary, with additional upside for non-financial improvements and overachievement:
- Target Opportunities: CEO (215%), CFO (115%), EVP (95%), Regional President (95%).
- Non-Financial Upside: Up to an additional 50% (CEO), 45% (CFO), and 30% (EVP/Regional President).
- Overachievement Upside: Up to an additional 35% (CEO), 65% (CFO), 75% (EVP), and 50% (Regional President).
Long-Term Equity Awards
Equity grants are scheduled for a grant date of March 1, 2025, vesting ratably over three years (except performance shares which vest after the period based on objectives):
| Executive | Stock Options | Time-Vesting RSU | Performance RSU |
|---|---|---|---|
| Tim L. Hingtgen | 200,000 | 200,000 | 400,000 |
| Kevin J. Hammons | 90,000 | 90,000 | 180,000 |
| Kevin A. Stockton | 40,000 | 40,000 | 80,000 |
| Chad A. Campbell | 25,000 | 25,000 | 50,000 |
Performance-based restricted stock is subject to objectives from January 1, 2025, to December 31, 2027, with vesting ranging from 0% to 200% of the target grant.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or general risk factors. The primary contingency noted is the performance-based nature of the equity awards, where the final share count depends on achieving specific objectives over a three-year period.
Investor Verification Checklist
- Verify the specific performance metrics tied to the 2025-2027 performance-based restricted stock awards.
- Confirm the total potential cash compensation exposure for the CEO, including base, target, and maximum upside scenarios.
- Review the definitive proxy statement for the 2024 annual meeting referenced in the filing for historical compensation context.
- Monitor the March 1, 2025, grant date for the formal issuance of the equity awards.